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Abstract
Resistance to systemic drug therapy is a major reason for the failure of anticancer therapies. Here, we tested doxorubicin-loaded
human serum albumin (HSA) nanoparticles in the neuroblastoma cell line UKF-NB-3 and its ABCB1-expressing sublines adapted
to vincristine (UKF-NB-3rVCR1) and doxorubicin (UKF-NB-3rDOX20). Doxorubicin-loaded nanoparticles displayed increased
anticancer activity in UKF-NB-3rVCR1 and UKF-NB-3rDOX20 cells relative to doxorubicin solution, but not in UKF-NB-3 cells.
UKF-NB-3rVCR1 cells were re-sensitised by nanoparticle-encapsulated doxorubicin to the level of UKF-NB-3 cells. UKF-NB-
3rDOX20 cells displayed a more pronounced resistance phenotype than UKF-NB-3rVCR1 cells and were not re-sensitised by
doxorubicin-loaded nanoparticles to the level of parental cells. ABCB1 inhibition using zosuquidar resulted in similar effects like
nanoparticle incorporation, indicating that doxorubicin-loaded nanoparticles successfully circumvent ABCB1-mediated drug efflux.
The limited re-sensitisation of UKF-NB-3rDOX20 cells to doxorubicin by circumvention of ABCB1-mediated efflux is probably
due to the presence of multiple doxorubicin resistance mechanisms. So far, ABCB1 inhibitors have failed in clinical trials probably
because systemic ABCB1 inhibition results in a modified body distribution of its many substrates including drugs, xenobiotics, and
other molecules. HSA nanoparticles may provide an alternative, more specific way to overcome transporter-mediated resistance.
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Table 1: Nanoparticle diameter, polydispersity, and drug load.
Nanoparticle formulations Diameter (nm) Polydispersity Drug load (µg doxorubicin/mg nanoparticle)
HSA (0%) 848.7 0.500 370.9
HSA (40%) 485.8 0.189 151.9
HSA (100%) 496.4 0.213 190.5
HSA (200%) 463.4 0.153 164.8
Introduction
According to Globocan there "were 14.1 million new cancer
cases, 8.2 million cancer deaths and 32.6 million people living
with cancer (within 5 years of diagnosis) in 2012 worldwide"
[1]. Despite substantial improvements over recent decades, the
prognosis for many cancer patients remains unacceptably poor.
The outlook is particularly grim for patients that are diagnosed
with disseminated (metastatic) disease who cannot be success-
fully treated by local treatment (surgery, radiotherapy) and
depend on systemic drug therapy, because the success of sys-
temic therapies is typically limited by therapy resistance [2-4].
Drug efflux mediated by transporters including adenosine
triphosphate (ATP)-binding cassette (ABC) transporters has
been shown to play a crucial role in cancer cell drug resistance
[2,5]. ABCB1 (also known as P-glycoprotein or MDR1) seems
to play a particularly important role in cancer cell drug resis-
tance as a highly promiscuous transporter that mediates the cel-
lular efflux of a wide range of structurally different substrates
including many anticancer drugs. Different studies have re-
ported that nanometer-sized drug carrier systems can bypass
efflux-mediated drug resistance [6]. This includes various nano-
particle and liposome formulations of the ABCB1 substrate
doxorubicin [7-12].
Here, we here investigated the effects of doxorubicin-loaded
human serum albumin (HSA) nanoparticles in ABCB1-
expressing neuroblastoma cells. HSA nanoparticles are easy to
produce [13-17], and HSA is a well-tolerated material. It is the
most abundant protein in human blood plasma and used in
many pharmaceutical formulations, in particular as part of criti-
cal care treatment [18].
Results
Nanoparticle size, polydispersity and drug
load
HSA nanoparticles were prepared by desolvation as previously
described [13-17]. The nanoparticles were stabilised by the
cross-linking of free amino groups present in albumin. Three
different nanoparticle preparations were produced using
glutaraldehyde at amounts that corresponded to a theoretical
cross-linking of 40% (HSA 40% nanoparticles), 100% (HSA
100% nanoparticles), or 200% (HSA 200% nanoparticles) of
the amino groups that are available in the HSA molecules. A
nonstabilised (0% cross-linking) formulation was used as a
control. The resulting particle sizes and polydispersity indices
are shown in Table 1. HSA (0%) nanoparticles displayed a large
particle size of almost 1 µm and a high polydispersity of 0.5,
confirming that no stable nanoparticles had formed (Table 1).
The three HSA nanoparticle preparations stabilised by the dif-
ferent glutaraldehyde concentrations displayed similar diame-
ters between 460 and 500 nm and polydispersity indices in the
range of 0.153 and 0.213, indicating a narrow but not monodis-
perse size distribution (Table 1).
The spherical shape and narrow size distribution of HSA nano-
particles was confirmed by scanning electron microscopy
(SEM) as depicted for nanoparticles stabilised by a 100% cross-
linking degree (Figure 1). For these nanoparticles a zeta poten-
tial of −12.5 ± 1.8 mV (n = 6) was detected, indicating only a
moderate stabilisation by electrostatic repulsion.
While HSA (40%), HSA (100%), and HSA (200%) nanoparti-
cles displayed similar drug loads between 152 and 191 µg
doxorubicin/mg nanoparticle, HSA (0%) nanoparticles had
bound 371 µg doxorubicin/mg HSA (Table 1). This probably
reflected the higher accessibility of doxorubicin binding sites,
which are known to be available on HSA [19], in HSA mole-
cules in solution compared to the accessible binding sites avail-
able in HSA nanoparticles.
Doxorubicin sensitivity of the used
neuroblastoma cell lines
The parental neuroblastoma cell line UKF-NB-3 and its doxoru-
bicin- (UKF-NB-3rDOX20) and vincristine-adapted (UKF-NB-
3rVCR1) sub-lines substantially differed in their doxorubicin
sensitivity (Figure 2). UKF-NB-3 displayed the lowest doxoru-
bicin IC50 (3.8 ng/mL). UKF-NB-3rVCR1 was 4-fold more
resistant to doxorubicin than UKF-NB-3 (doxorubicin IC50:
15.5 ng/mL). UKF-NB-3rDOX20 showed the highest doxoru-
bicin IC50 (89.0 ng/mL), resulting in a 23-fold increase in
doxorubicin resistance compared to UKF-NB-3 (Figure 2, Sup-
porting Information File 1, Table S1).
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Figure 1: SEM confirmed the spherical shape and narrow size distribution of doxorubicin-loaded HSA (100%) nanoparticles.
Figure 2: Doxorubicin sensitivity of UKF-NB-3, its doxorubicin-adapted
sub-line UKF-NB-3rDOX20 and its vincristine-adapted sub-line UKF-
NB-3rVCR1. A) Doxorubicin concentrations that reduce cell viability by
50% (IC50) as indicated by MTT assay after 120 h of incubation. B)
Fold change in doxorubicin sensitivity (doxorubicin IC50 UKF-NB-3
sub-line/doxorubicin IC50 UKF-NB-3). Numerical values are presented
in Supporting Information File 1, Table S1. *P < 0.05 relative to UKF-
NB-3.
Effects of doxorubicin-loaded nanoparticles
on neuroblastoma cells
The effects of doxorubicin applied in solution or incorporated
into HSA (0%), HSA (40%), HSA (100%), or HSA (200%)
nanoparticles on neuroblastoma cell viability are shown in
Figure 3. The numerical values are presented in Supporting
Information File 1, Table S1. Empty control nanoparticles did
not affect cell viability in the investigated concentrations.
In the neuroblastoma cell line UKF-NB-3, the nanoparticle
preparations displayed similar activity as doxorubicin solution,
with doxorubicin-loaded HSA (40%), HSA (100%), and HSA
(200%) nanoparticles potentially showing a trend towards a
slightly increased activity (Figure 3). However, the differences
did not reach statistical significance. Similar results were ob-
tained in the doxorubicin-adapted UKF-NB-3 sub-line UKF-
NB-3rDOX20, although the difference between doxorubicin-
loaded HSA (200%) nanoparticles and doxorubicin solution
reached statistical significance (Figure 3). Notably, non-
stabilised doxorubicin-bound HSA (0%) nanoparticles differed
in their relative activity and did not reduce UKF-NB-3rDOX20
viability by 50% within the observed concentration range up to
200 ng/mL.
The vincristine-adapted UKF-NB-3 sub-line UKF-NB-3rVCR1
displayed decreased doxorubicin sensitivity. However, doxoru-
bicin-loaded HSA (40%), HSA (100%), and HSA (200%) nano-
particles displayed a higher relative potency compared to
doxorubicin solution in UKF-NB-3rVCR1 (Figure 3, Figure 4).
The fold sensitisation doxorubicin IC50 doxorubicin solution/
doxorubicin IC50 nanoparticle-bound doxorubicin for HSA
(40%), HSA (100%), and HSA (200%) nanoparticles
(3.6–4.5-fold) was higher than for UKF-NB-3 (1.9–2.5-fold),
and UKF-NB-3rDOX20 (2.1–2.9-fold). The differences be-
tween doxorubicin-loaded HSA (40%) nanoparticles, HSA
(100%) nanoparticles, and HSA (200%) nanoparticles and
doxorubicin solution reached statistical significance (P < 0.05)
(Figure 3). Doxorubicin encapsulation into HSA (40%), HSA
(100%), or HSA (200%) nanoparticles reduced the doxorubicin
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Figure 3: Effects of doxorubicin (Dox) applied as a solution or incorpo-
rated into human serum albumin (HSA) nanoparticles on neuroblas-
toma cell viability. The investigated nanoparticles differed in the
amount of the cross-linker glutaraldehyde that was used for nanoparti-
cle stabilisation. The amount of glutaraldehyde corresponded to 40%
(Dox HSA (40%) NP), 100% (Dox HSA (100%) NP), or 200% (Dox
HSA (200%) NP) theoretical cross-linking of the available amino
groups present on HSA. Preparations prepared without glutaralde-
hyde served as a control (Dox HSA (0%) NP). Values are expressed
as concentrations that reduce cell viability by 50% (IC50) as deter-
mined by MTT assay after 120 h of incubation. Numerical values are
presented in Supporting Information File 1, Table S1. Empty nanoparti-
cles did not affect cell viability in the investigated concentrations.
*P < 0.05 relative to doxorubicin solution; # IC50 > 200 ng/mL.
IC50 in UKF-NB-3rVCR1 cells to the levels of doxorubicin
solution in parental UKF-NB-3 cells (Figure 3, Supporting
Information File 1, Table S1). In contrast, the doxorubicin IC50
of doxorubicin-loaded HSA nanoparticles remained clearly
(8–11-fold) higher in UKF-NB-3rDOX20 cells than the doxoru-
bicin IC50 of doxorubicin solution in parental UKF-NB-3 cells.
Effects of the ABCB1 inhibitor zosuquidar on
the efficacy of nanoparticle-bound
doxorubicin in UKF-NB-3rDOX20 cells
Doxorubicin is an ABCB1 substrate, and UKF-NB-3rDOX20
cells are characterised by high ABCB1 expression [20,21].
Figure 4: Fold sensitisation to doxorubicin by doxorubicin-bound nano-
particles (NPs). Values are expressed as fold changes doxorubicin
(Dox) IC50 of doxorubicin solution/doxorubicin IC50 of doxorubicin-
bound NPs. Human serum albumin (HSA) nanoparticles were
stabilised by glutaraldehyde concentrations corresponding to 40%
(Dox HSA (40%) NP), 100% (Dox HSA (100%) NP), or 200% (Dox
HSA (200%) NP) theoretical cross-linking of the available amino
groups present on HSA.
Vincristine is also an ABCB1 substrate, and vincristine-adapted
cancer cell lines often display enhanced ABCB1 levels
[20,22,23]. Accordingly, UKF-NB-3rVCR1 cells are sensitised
by the ABCB1 inhibitor zosuquidar [2-6] to doxorubicin to the
level of parental UKF-NB-3 cells (Supporting Information
File 1, Figure S1), which indicates that ABCB1 expression con-
tributes to the resistance phenotype observed in UKF-NB-
3rVCR1 cells.
Doxorubicin bound to nanometer-sized drug carrier systems has
been shown to bypass ABCB1-mediated drug efflux [7-12]. In
UKF-NB-3rVCR1 cells, combining both doxorubicin with
zosuquidar and doxorubicin encapsulation into HSA nanoparti-
cles reduced the doxorubicin IC50 to the level of parental UKF-
NB-3 cells (Figure 3, Supporting Information File 1, Figure S1,
Table S1), which do not display detectable ABCB1 activity
[20,22,23]. Hence, the increased activity of nanoparticle-bound
doxorubicin that we observed in UKF-NB-3rVCR10 cells is
likely to be attributed to the circumvention of ABCB1-medi-
ated doxorubicin efflux.
In UKF-NB-3rDOX20 cells, however, the differences between
doxorubicin solution and doxorubicin nanoparticles only
reached statistical significance for doxorubicin-loaded HSA
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(200%) nanoparticles (Figure 3). The reasons for this may
include that nanoparticle-incorporated doxorubicin does not
completely avoid ABCB1-mediated efflux from UKF-NB-
3rDOX20 cells and/or that doxorubicin resistance is caused by
multiple resistance mechanisms and that avoidance of ABCB1-
mediated transport is not sufficient to re-sensitise UKF-NB-
3rDOX20 cells to doxorubicin to the level of UKF-NB-3 cells.
To further study the role of ABCB1 as a doxorubicin resistance
mechanism in UKF-NB-3rDOX20 cells, we performed addition-
al experiments in which we combined the ABCB1 inhibitor
zosuquidar and doxorubicin applied as a solution or nanoparti-
cle preparations in UKF-NB-3rDOX20 and UKF-NB-3 cells.
Zosuquidar (1 µM) did not affect the efficacy of doxorubicin
solution or nanoparticle-bound doxorubicin in parental UKF-
NB-3 cells (Figure 5), which do not display noticeable ABCB1
activity [20,22,23]. These experiments also confirmed that there
is no significant difference in the anticancer activity between
doxorubicin solution and doxorubicin nanoparticles in UKF-
NB-3 cells, despite an apparent trend in the first set of experi-
ments (Figure 3).
In UKF-NB-3rDOX20 cells, the addition of zosuquidar resulted
in an increased sensitivity to free doxorubicin (Figure 5). The
doxorubicin IC50 decreased by 2.5-fold from 91 ng/mL in the
absence of zosuquidar to 37 ng/mL in the presence of
zosuquidar, but not to the level of UKF-NB-3 cells (4.6 ng/mL)
(Supporting Information File 1, Table S2). This confirmed that
ABCB1 is one among multiple resistance mechanisms that con-
tribute to the doxorubicin resistance phenotype observed in
UKF-NB-3rDOX20.
In this set of experiments, doxorubicin-loaded nanoparticles
displayed a significantly increased activity compared to doxoru-
bicin solution in UKF-NB-3rDOX20 cells (Figure 5). This
finding together with the non-significant trend observed in the
first set of experiments (Figure 3) suggests that doxorubicin-
loaded nanoparticles do indeed exert stronger effects against
UKF-NB-3rDOX20 cells than doxorubicin solution. Zosuquidar
only moderately increased the efficacy of doxorubicin
nanoparticles further (1.1–1.8-fold) in UKF-NB-3rDOX20 cells
(Figure 5, Supporting Information File 1, Table S2). In particu-
lar, the anticancer effects of doxorubicin-loaded HSA (200%)
nanoparticles, the most active nanoparticle preparation in UKF-
NB-3rDOX20 cells, displayed a doxorubicin IC50 of 20 ng/mL,
which was not further reduced by addition of zosuquidar
(doxorubicin IC50: 18 ng/mL) (Figure 5, Table S2). Hence, the
increased anticancer activity of doxorubicin incorporated into
HSA nanoparticles appears to be primarily caused by circum-
venting the ABCB1-mediated doxorubicin efflux in UKF-NB-
3rDOX20 cells.
Figure 5: Doxorubicin (Dox) concentrations that reduce neuroblas-
toma cell viability by 50% (IC50) in the presence or absence of the
ABCB1 inhibitor zosuquidar (1 µM) as determined by MTT assay after
120 h incubation. Doxorubicin was either applied as a solution or incor-
porated into human serum albumin (HSA) nanoparticles which had
been stabilised by addition of glutaraldehyde concentrations corre-
sponding to 40% (Dox HSA (40%) NP), 100% (Dox HSA (100%) NP),
or 200% (Dox HSA (200%) NP) theoretical cross-linking of the avail-
able amino groups present on HSA. Zosuquidar (1 µM) did not affect
cell viability on its own. Numerical data are presented in Supporting
Information File 1, Table S2. *P < 0.05 relative to the doxorubicin IC50
in the absence of zosuquidar; §P < 0.05 relative to doxorubicin solu-
tion.
Discussion
The occurrence of drug resistance is the major reason for the
failure of systemic anticancer therapies [2]. Here, we investigat-
ed the effects of doxorubicin-loaded HSA nanoparticles on the
viability of the neuroblastoma cell line UKF-NB-3 and its sub-
lines adapted to doxorubicin (UKF-NB-3rDOX20) and
vincristine (UKF-NB-3rVCR1), which both display ABCB1 ac-
tivity and resistance to doxorubicin. The HSA nanoparticles
were prepared by desolvation and stabilised by glutaraldehyde,
which crosslinks amino groups present in albumin molecules
[13-17]. Glutaraldehyde was used at molar concentrations that
corresponded to 40% (Dox HSA (40%) nanoparticles), 100%
(Dox HSA (100%) nanoparticles), or 200% (Dox HSA (200%)
nanoparticles) theoretical cross-linking of the 59 amino groups
Beilstein J. Nanotechnol. 2019, 10, 1707–1715.
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available per HSA molecule [24]. The resulting nanoparticles
ranged from 463 to 486 nm in diameter and had a low polydis-
persity index in the range of 0.2.
Doxorubicin-loaded nanoparticles displayed similar activity as
doxorubicin solution in the parental UKF-NB-3 cell line, but
exerted stronger effects than doxorubicin solution in the
ABCB1-expressing UKF-NB-3 sub-lines. The UKF-NB-
3rVCR1 cells were similarly sensitive to doxorubicin-loaded
nanoparticles as parental UKF-NB-3 cells to doxorubicin solu-
tion (and doxorubicin-loaded nanoparticles). This suggests that
the doxorubicin resistance of UKF-NB-3rVCR1 cells exclusive-
ly depends on ABCB1 expression. In concordance, the ABCB1
inhibitor zosuquidar re-sensitised UKF-NB-3rVCR1 cells to the
level of parental UKF-NB-3 cells.
The UKF-NB-3rDOX20 cells displayed a more pronounced
doxorubicin resistance phenotype than UKF-NB-3rVCR1 cells
and were neither re-sensitised by nanoparticle-encapsulated
doxorubicin nor by zosuquidar to the level of UKF-NB-3 cells.
This suggests that UKF-NB-3rDOX20 cells have developed
multiple doxorubicin resistance mechanisms. In contrast, adap-
tation of UKF-NB-3rVCR1 cells to vincristine, a tubulin-
binding agent with an anticancer mechanism of action that is
not related to that of the topoisomerase II inhibitor doxorubicin
[2,20,25,26], did not result in the acquisition of changes that
confer doxorubicin resistance beyond ABCB1 expression.
Furthermore, zosuquidar did not increase the efficacy of
doxorubicin-loaded HSA (100%) and HSA (200%) nanoparti-
cles and only modestly enhanced the efficacy of doxorubicin-
loaded HSA (40%) nanoparticles. Together, these data confirm
that administration of doxorubicin as HSA nanoparticles
resulted in the circumvention of ABCB1-mediated drug efflux.
The difference between HSA (40%) nanoparticles and the other
two preparations may be explained by elevated drug release due
to the lower degree of cross-linking.
Interestingly, high concentrations of the cross-linker glutaralde-
hyde did not affect the efficacy of the resulting doxorubicin-
loaded nanoparticles although high glutaraldehyde concentra-
tions might have been expected to affect drug release and/or to
covalently bind to doxorubicin via its amino group.
Notably, the results differ from a recent similar study in which
nanoparticles prepared from poly(lactic-co-glycolic acid)
(PLGA) or polylactic acid (PLA), two other biodegradable ma-
terials approved by the FDA and EMA for human use [27,28],
did not bypass ABCB1-mediated drug efflux [29]. Differences
in the mode of uptake and cellular distribution of the nanoparti-
cles from different materials may be responsible for these
discrepancies. HSA nanoparticles may be internalised upon
interaction with cellular albumin receptors [30,31]. Notably,
nab-paclitaxel, an HSA nanoparticle-based preparation of pacli-
taxel (another ABCB1 substrate [21]), which is approved for
the treatment of different forms of cancer [32], had previously
been shown not to avoid ABCB1-mediated drug efflux [33].
However, nab-paclitaxel is not produced by the use of cross-
linkers, and the interaction of paclitaxel with albumin may
differ from that of doxorubicin. Hence, variations in drug
binding and drug release kinetics may be responsible for this
difference.
Despite the prominent role of ABCB1 as a drug resistance
mechanism, attempts to exploit it as drug target have failed so
far, despite the development of highly specific allosteric
ABCB1 inhibitors (of which zosuquidar is one) [5,21]. One
reason for this is that ABCB1 is expressed at various physiolog-
ical borders and involved in the control of the body distribution
of its many endogenous and exogenous substrates. Systemic
ABCB1 inhibition can therefore result in toxicity as a conse-
quence of a modified body distribution of anticancer drugs (and
other drugs that are co-administered for conditions other than
cancer), xenobiotics, and other molecules. Hence, the use of
drug carrier systems to bypass ABC transporter-mediated drug
efflux is conceptually very attractive because it can (in contrast
to inhibitors of ABCB1 or other transporters) overcome resis-
tance mediated by multiple transporters and does not result in
the systemic inhibition of transporter function at physiological
barriers. However, cancer cells may be characterised by
multiple further resistance mechanisms and just bypassing
transporter-mediated efflux may not be sufficient to achieve
therapeutic response (as illustrated by our current finding that
UKF-NB-3rDOX20 cells cannot be fully re-sensitised to
doxorubicin by zosuquidar) [2,5,21]. Hence, our results demon-
strate that more sophisticated, personalised therapies will need
to be developed. Such therapies will depend on an improved
understanding of the resistance status of cancer cells to a certain
drug beyond its transporter status. If biomarkers become avail-
able that predict cancer cell response to a certain drug more reli-
ably, nanoparticles can be used to transport drugs under circum-
vention of transporter-mediated efflux into cancer cells that are
likely to respond to them.
In conclusion, doxorubicin-loaded HSA nanoparticles pro-
duced by desolvation and cross-linking using glutaraldehyde
overcome (in contrast to other nanoparticle systems) trans-
porter-mediated drug resistance in drug-adapted neuroblastoma
cells. However, our data also show that bypassing of trans-
porter-mediated drug efflux may not be sufficient to sensitise
cancer cells, which have developed multiple resistance mecha-
nisms, to the level of sensitive parental cells.




HSA and glutaraldehyde were obtained from Sigma-Aldrich
Chemie GmbH (Karlsruhe, Germany). Dulbecco's phosphate
buffered saline (PBS) was purchased from Biochrom GmbH
(Berlin, Germany). Doxorubicin was obtained from LGC Stan-
dards GmbH (Wesel, Germany). All chemicals were of analyti-
cal grade and used as received.
Human serum albumin (HSA) nanoparticle
preparation by desolvation
HSA nanoparticles were prepared by desolvation as previously
described [13-17]. 100 µL of a 1% (w/v) aqueous doxorubicin
solution was added to 500 µL of a 40 mg/mL (w/v) HSA solu-
tion and incubated for 2 h at room temperature under stirring
(550 rpm, Cimaric i Multipoint Stirrer, ThermoFisher Scien-
tific, Langenselbold, Germany). 4 mL of ethanol 96% was
added at room temperature under stirring using a peristaltic
pump (Ismatec ecoline, Ismatec, Wertheim-Mondfeld,
Germany) at a flow rate of 1 mL/min. After the desolvation
process, the resulting nanoparticles were stabilised/cross-linked
using different amounts of glutaraldehyde that corresponded to
different percentages of the theoretical amount that is necessary
for the quantitative cross-linking of the 60 primary amino
groups present in the HSA molecules of the particle matrix. The
addition of 4.7 µL 8% (w/v) aqueous glutaraldehyde solution
resulted in a theoretical cross-linking of 40% of the HSA amino
groups, the addition of 11.8 µL 8% (w/v) aqueous glutaralde-
hyde solution in 100% cross-linking, and the addition of
23.6 µL 8% (w/v) aqueous glutaraldehyde solution in
200% cross-linking. The suspension was then stirred for 12 h at
550 rpm. The particles were purified by centrifugation (at
16,000g for 12 min) and resuspension steps performed three
times in purified water. During the particle purification the
supernatants were collected and the drug content was measured
by high-performance liquid chromatography (HPLC) as de-
scribed below. The loading efficiency of doxorubicin in the
nanoparticles was calculated based on the difference between
the doxorubicin amount used for nanoparticle preparation and
the unbound amount detected in the collected supernatants.
Determination of particle size distribution
The average particle size and the polydispersity were measured
by photon correlation spectroscopy (PCS) using a Malvern zeta-
sizer nano instrument (Malvern Instruments, Herrenberg,
Germany). The resulting particle suspensions were diluted
1:100 with purified water and measured at a temperature of
22 °C using a backscattering angle of 173°.
The zeta potential was measured in the same instrument by
laser Doppler microelectrophoresis to provide information
about the surface charge of the nanoparticles. Thus, the nano-
particle dilutions described above were transferred into a folded
capillary cell and the experiment was conducted at 22 °C.
Morphological analysis of nanoparticles by
scanning electron microscopy (SEM)
3 µL of diluted HAS nanoparticle suspension (0.25 mg/mL)
was applied on a 0.1 µm membrane filter (IsoporeTM mem-
brane filter, Merck Millipore, Darmstadt, Germany) and dried
overnight in a desiccator. Afterwards, the membrane filter was
sputtered with gold (Sputter SCD 040, BALTEC, Liechtenstein)
under argon atmosphere. SEM was performed on a CamScan
CS4 microscope (Cambridge Scanning Company, Cambridge,
United Kingdom) and the sample was visualised with an accel-
erating voltage of 10 kV, a working distance of 10 mm, and
10,000-fold magnification.
Doxorubicin quantification via HPLC-UV
The amount of doxorubicin that was incorporated into the nano-
particles was determined by HPLC-UV (HPLC 1200 series,
Agilent Technologies GmbH, Böblingen, Germany) using a
LiChroCART 250 × 4 mm LiChrospher 100 RP 18 column
(Merck KGaA, Darmstadt, Germany). The mobile phase was a
mixture of water and acetonitrile (70:30) containing 0.1% tri-
fluoroacetic acid [16]. In order to obtain symmetric peaks a
gradient was used. In the first 6 min the percentage of A was
reduced from 70% to 50%. Subsequently within 2 min the
amount of A was further decreased to 20% and then within
another 2 min increased again to 70%. These conditions were
held for a final 5 min, resulting in a total runtime of 15 min.
While using a flow rate of 0.8 mL/min, an elution time for
doxorubicin of t = 7.5 min was achieved. The detection of
doxorubicin was performed at a wavelength of 485 nm [34].
Cell culture
The neuroblastoma cell line UKF-NB-3, which harbours a
MYCN amplification (a major indicator of high-risk disease
and poor prognosis [35]), was established from a stage 4
neuroblastoma patient [20]. The UKF-NB-3 sub-lines adapted
to growth in the presence of doxorubicin 20 ng/mL (UKF-NB-
3rDOX20) [20] or vincristine 1 ng/mL (UKF-NB-3rVCR1)
were established by continuous exposure to step-wise increas-
ing drug concentrations as previously described [20,36] and
derived from the resistant cancer cell line (RCCL) collection
[37].
All cells were propagated in Iscove’s modified Dulbecco’s me-
dium (IMDM) supplemented with 10% foetal calf serum,
100 IU/mL penicillin and 100 µg/mL streptomycin at 37 °C.
The drug-adapted sub-lines were continuously cultured in the
presence of the indicated drug concentrations. The cells were
Beilstein J. Nanotechnol. 2019, 10, 1707–1715.
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routinely tested for mycoplasma contamination and authenti-
cated by short tandem repeat profiling.
Cell viability assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay modified after
Mosman [38], as previously described [39]. 2 × 104 cells
suspended in 100 µL of cell culture medium were plated per
well in 96-well plates and incubated in the presence of various
doxorubicin concentrations (free or nanoparticle-encapsulated)
for 120 h. Where indicated, free or nanoparticle-encapsulated
doxorubicin was combined with a fixed concentration of 1 µM
of the ABCB1 inhibitor zosuquidar. Then, 25 µL of MTT solu-
tion (2 mg/mL (w/v) in PBS) was added per well, and the plates
were incubated at 37 °C for an additional 4 h. After this, the
cells were lysed using 200 µL of a buffer containing 20% (w/v)
sodium dodecylsulfate and 50% (v/v) N,N-dimethylformamide
with the pH adjusted to 4.7 at 37 °C for 4 h. The absorbance
was determined at 570 nm for each well using a 96-well multi-
scanner. After subtracting of the background absorption, the
results are expressed as percentage viability relative to control
cultures which received no drug. The drug concentrations that
inhibited cell viability by 50% (IC50) were determined using
CalcuSyn (Biosoft, Cambridge, UK).
Statistical testing
The results are expressed as the mean ± standard deviation of at
least three experiments. The Student’s t-test was used for
comparing two groups. Three and more groups were compared
by ANOVA followed by the Student–Newman–Keuls test.
P-values lower than 0.05 were considered to be significant.
Supporting Information
Doxorubicin IC50s in neuroblastoma cells in the absence or
presence of the ABCB1 inhibitor zosuquidar. Effects of
doxorubicin applied as solution or incorporated into HSA
nanoparticles on neuroblastoma cell viability. Effects of
doxorubicin solution or doxorubicin HSA nanoparticles on
neuroblastoma cells with or without zosuquidar.





This work was supported by the Kent Cancer Trust, the Hilfe
für krebskranke Kinder Frankfurt e.V., and the Frankfurter
Stiftung für krebskranke Kinder.
ORCID® iDs
Mark N. Wass - https://orcid.org/0000-0001-5428-6479
Klaus Langer - https://orcid.org/0000-0002-0203-7478
Martin Michaelis - https://orcid.org/0000-0002-5710-5888
Preprint
A non-peer-reviewed version of this article has been previously published
as a preprint doi:10.1101/655662
References
1. International Agency for Research on Cancer. Cancer Fact Sheets.
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed Sept
10, 2018).
2. Holohan, C.; Van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G.
Nat. Rev. Cancer 2013, 13, 714–726. doi:10.1038/nrc3599
3. Steeg, P. S. Nat. Rev. Cancer 2016, 16, 201–218.
doi:10.1038/nrc.2016.25
4. Siegel, R. L.; Miller, K. D.; Jemal, A. Ca-Cancer J. Clin. 2018, 68, 7–30.
doi:10.3322/caac.21442
5. Robey, R. W.; Pluchino, K. M.; Hall, M. D.; Fojo, A. T.; Bates, S. E.;
Gottesman, M. M. Nat. Rev. Cancer 2018, 18, 452–464.
doi:10.1038/s41568-018-0005-8
6. Bar-Zeev, M.; Livney, Y. D.; Assaraf, Y. G. Drug Resist. Updates 2017,
31, 15–30. doi:10.1016/j.drup.2017.05.002
7. Thierry, A. R.; Vigé, D.; Coughlin, S. S.; Belli, J. A.; Dritschilo, A.;
Rahman, A. FASEB J. 1993, 7, 572–579.
doi:10.1096/fasebj.7.6.8097173
8. Bennis, S.; Chapey, C.; Robert, J.; Couvreur, P. Eur. J. Cancer 1994,
30, 89–93. doi:10.1016/s0959-8049(05)80025-5
9. Wong, H. L.; Bendayan, R.; Rauth, A. M.; Xue, H. Y.; Babakhanian, K.;
Wu, X. Y. J. Pharmacol. Exp. Ther. 2006, 317, 1372–1381.
doi:10.1124/jpet.106.101154
10. Prados, J.; Melguizo, C.; Ortiz, R.; Velez, C.; Alvarez, P. J.; Arias, J. L.;
Ruiz, M. A.; Gallardo, V.; Aranega, A. Anti-Cancer Agents Med. Chem.
2012, 12, 1058–1070. doi:10.2174/187152012803529646
11. Oliveira, M. S.; Aryasomayajula, B.; Pattni, B.; Mussi, S. V.;
Ferreira, L. A. M.; Torchilin, V. P. Int. J. Pharm. 2016, 512, 292–300.
doi:10.1016/j.ijpharm.2016.08.049
12. Maiti, C.; Parida, S.; Kayal, S.; Maiti, S.; Mandal, M.; Dhara, D.
ACS Appl. Mater. Interfaces 2018, 10, 5318–5330.
doi:10.1021/acsami.7b18245
13. Weber, C.; Kreuter, J.; Langer, K. Int. J. Pharm. 2000, 196, 197–200.
doi:10.1016/s0378-5173(99)00420-2
14. Langer, K.; Balthasar, S.; Vogel, V.; Dinauer, N.; von Briesen, H.;
Schubert, D. Int. J. Pharm. 2003, 257, 169–180.
doi:10.1016/s0378-5173(03)00134-0
15. Langer, K.; Anhorn, M. G.; Steinhauser, I.; Dreis, S.; Celebi, D.;
Schrickel, N.; Faust, S.; Vogel, V. Int. J. Pharm. 2008, 347, 109–117.
doi:10.1016/j.ijpharm.2007.06.028
16. Dreis, S.; Rothweiler, F.; Michaelis, M.; Cinatl, J., Jr.; Kreuter, J.;
Langer, K. Int. J. Pharm. 2007, 341, 207–214.
doi:10.1016/j.ijpharm.2007.03.036
17. von Storp, B.; Engel, A.; Boeker, A.; Ploeger, M.; Langer, K.
J. Microencapsulation 2012, 29, 138–146.
doi:10.3109/02652048.2011.635218
Beilstein J. Nanotechnol. 2019, 10, 1707–1715.
1715
18. Ferrer, R.; Mateu, X.; Maseda, E.; Yébenes, J. C.; Aldecoa, C.;
De Haro, C.; Ruiz-Rodriguez, J. C.; Garnacho-Montero, J.
Expert Rev. Clin. Pharmacol. 2018, 11, 125–137.
doi:10.1080/17512433.2018.1412827
19. Elzoghby, A. O.; Samy, W. M.; Elgindy, N. A. J. Controlled Release
2012, 157, 168–182. doi:10.1016/j.jconrel.2011.07.031
20. Kotchetkov, R.; Driever, P.; Cinatl, J.; Michaelis, M.; Karaskova, J.;
Blaheta, R.; Squire, J.; Von Deimling, A.; Moog, J.; Cinatl, J., Jr.
Int. J. Oncol. 2005, 27, 1029–1037. doi:10.3892/ijo.27.4.1029
21. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.;
Gottesman, M. M. Nat. Rev. Drug Discovery 2006, 5, 219–234.
doi:10.1038/nrd1984
22. Michaelis, M.; Rothweiler, F.; Klassert, D.; von Deimling, A.; Weber, K.;
Fehse, B.; Kammerer, B.; Doerr, H. W.; Cinatl, J., Jr. Cancer Res.
2009, 69, 416–421. doi:10.1158/0008-5472.can-08-1856
23. Michaelis, M.; Rothweiler, F.; Löschmann, N.; Sharifi, M.;
Ghafourian, T.; Cinatl, J., Jr. Oncotarget 2015, 6, 17605–17620.
doi:10.18632/oncotarget.2889
24. Carter, D. C.; Ho, J. X. Adv. Protein Chem. 1994, 45, 153–203.
doi:10.1016/s0065-3233(08)60640-3
25. Kavallaris, M. Nat. Rev. Cancer 2010, 10, 194–204.
doi:10.1038/nrc2803
26. Wijdeven, R. H.; Pang, B.; Assaraf, Y. G.; Neefjes, J.
Drug Resist. Updates 2016, 28, 65–81. doi:10.1016/j.drup.2016.07.001
27. Wischke, C.; Schwendeman, S. P. Int. J. Pharm. 2008, 364, 298–327.
doi:10.1016/j.ijpharm.2008.04.042
28. Tyler, B.; Gullotti, D.; Mangraviti, A.; Utsuki, T.; Brem, H.
Adv. Drug Delivery Rev. 2016, 107, 163–175.
doi:10.1016/j.addr.2016.06.018
29. Pieper, S.; Onafuye, H.; Mulac, D.; Cinatl, J., Jr.; Wass, M. N.;
Michaelis, M.; Langer, K. bioRxiv, Pharmacol. Toxicol. 2018.
doi:10.1101/403923
30. Merlot, A. M.; Kalinowski, D. S.; Richardson, D. R. Front. Physiol.
2014, 5, 299. doi:10.3389/fphys.2014.00299
31. Hyun, H.; Park, J.; Willis, K.; Park, J. E.; Lyle, L. T.; Lee, W.; Yeo, Y.
Biomaterials 2018, 180, 206–224.
doi:10.1016/j.biomaterials.2018.07.024
32. Brufsky, A. Exp. Hematol. Oncol. 2017, 6, 7.
doi:10.1186/s40164-017-0066-5
33. Vallo, S.; Köpp, R.; Michaelis, M.; Rothweiler, F.; Bartsch, G.;
Brandt, M. P.; Gust, K. M.; Wezel, F.; Blaheta, R. A.; Haferkamp, A.;
Cinatl, J., Jr. Oncol. Lett. 2017, 13, 4085–4092.
doi:10.3892/ol.2017.5986
34. Sanson, C.; Schatz, C.; Le Meins, J.-F.; Soum, A.; Thévenot, J.;
Garanger, E.; Lecommandoux, S. J. Controlled Release 2010, 147,
428–435. doi:10.1016/j.jconrel.2010.07.123
35. Fletcher, J. I.; Ziegler, D. S.; Trahair, T. N.; Marshall, G. M.; Haber, M.;
Norris, M. D. Nat. Rev. Cancer 2018, 18, 389–400.
doi:10.1038/s41568-018-0003-x
36. Michaelis, M.; Rothweiler, F.; Barth, S.; Cinatl, J.; van Rikxoort, M.;
Löschmann, N.; Voges, Y.; Breitling, R.; von Deimling, A.; Rödel, F.;
Weber, K.; Fehse, B.; Mack, E.; Stiewe, T.; Doerr, H. W.; Speidel, D.;
Cinatl, J., Jr. Cell Death Dis. 2011, 2, e243.
doi:10.1038/cddis.2011.129
37. University of Kent. The Resistant Cancer Cell Line (RCCL) collection.
https://research.kent.ac.uk/industrial-biotechnology-centre/the-resistant
-cancer-cell-line-rccl-collection/ (accessed Oct 19, 2018).
38. Mosmann, T. J. Immunol. Methods 1983, 65, 55–63.
doi:10.1016/0022-1759(83)90303-4
39. Michaelis, M.; Matousek, J.; Vogel, J.-U.; Slavik, T.; Langer, K.;
Cinatl, J.; Kreuter, J.; Schwabe, D.; Cinatl, J., Jr. Anti-Cancer Drugs
2000, 11, 369–376. doi:10.1097/00001813-200006000-00007
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0). Please note
that the reuse, redistribution and reproduction in particular
requires that the authors and source are credited.
The license is subject to the Beilstein Journal of
Nanotechnology terms and conditions:
(https://www.beilstein-journals.org/bjnano)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjnano.10.166
